III CELESTIMO

Beyond's analysis on III CELESTIMO

• 2026-09-17 — Roche’s Lunsumio‑lenalidomide combo shows PFS gain in relapsed/refractory follicular lymphoma

Recent news mentioning III CELESTIMO

• 2026-09-17 — Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study

Appears alongside

• Roche Lunsumio-based

Browse the full archive →